MediWound (NasdaqGM:MDWD) opened Q1 2026 with revenue of US$1.5 million and a basic EPS loss of US$0.23, alongside a trailing twelve month basic EPS loss of US$2.19 on revenue of US$14.5 million. Over recent quarters the company has seen quarterly revenue move from US$3.96 million in Q1 2025 to US$5.71 million in Q2, US$5.43 million in Q3 and US$1.87 million in Q4. Quarterly basic EPS losses ranged between US$0.07 and US$1.23, setting the backdrop for the latest numbers and the growth expectations embedded in the story. With margins still under pressure and earnings firmly in the red, the key question for investors is how far potential revenue growth can carry the investment case from here.

See our full analysis for MediWound.

With the headline figures on the table, the next step is to set these results against the widely followed MediWound narratives to see which views the numbers support and which they call into question.

Losses Stay Heavy At US$26.1 Million Over The Year

• On a trailing twelve month basis to Q1 2026, MediWound booked a net loss of US$26.1 million on US$14.5 million of revenue, with basic EPS loss of US$2.19, compared with quarterly net losses that ranged from US$2.7 million to US$13.3 million over the past five reported quarters.
• Consensus narrative talks about expanding manufacturing capacity and new trials helping financial stability over time. However, the trailing twelve month loss staying above US$20 million in every period challenges that view by showing that, so far, operating scale has not translated into improving bottom line figures.
  • The Q2 2025 net loss of US$13.3 million and Q4 2025 loss of US$7.2 million sit well above Q1 2025's US$0.7 million loss. This means the path that analysts expect, with revenue growth of about 38.9% a year, is not yet showing up as improved net results in the historical data.
  • With analysts not expecting profitability within the next three years, the current loss profile supports the cautious part of the consensus view that calls out sustained high R&D and SG&A and the need for future funding as ongoing pressures.

Premium 12.7x P/S Relies On High Growth Forecasts

• The stock trades on a P/S of 12.7x compared with a peer average of 4x and a US pharmaceuticals industry average of 5.8x. Revenue forecasts of about 44.9% annual growth and a consensus analyst price target of US$30.67 sit against a current share price of US$14.33.
• Bulls point to that high growth outlook to justify the premium multiple and analyst upside, but the trailing twelve month revenue of US$14.5 million versus the forecast growth rate highlights how much of the bullish case still sits in the future rather than in current scale.
  • Analysts in the bullish camp reference revenue growth of around 29.5% a year and a future EPS figure of US$0.83 by 2028. Yet the latest annual EPS loss of US$2.19 shows the starting point is still deeply loss making.
  • The gap between the US$14.33 share price and the US$30.67 target, combined with the rich 12.7x P/S, means investors are being asked to pay well above peer levels today on the expectation that the high growth forecasts are achieved without profitability in the next three years.

On these numbers, bulls argue that rapid top line expansion can eventually support the premium valuation, while the current losses keep the debate alive over how long that thesis may take to play out. 🐂 MediWound Bull Case

Persistent Losses Reinforce Bearish Profitability Concerns

• Over the last six reported quarters, MediWound has reported a loss every time, with quarterly net losses between US$0.7 million and US$13.3 million and trailing twelve month losses between US$20.6 million and US$30.2 million, and analysts do not expect profitability within three years.
• Bears flag the ongoing losses and potential for future dilution, and the data on widening trailing losses and the absence of a near term profit forecast directly back up concerns about funding and earnings quality.
  • The trailing twelve month basic EPS loss sits between US$1.90 and US$3.03 through the periods shown, while the risks summary notes that losses have grown at about 17.8% a year over five years. This is consistent with the idea that cost growth has outpaced revenue so far.
  • With analysts expecting shares outstanding to grow by 3.47% a year and shareholders already having experienced dilution, the combination of persistent losses and expected share growth underpins the cautious view that any future earnings recovery could be spread over a larger share base.

Skeptics point to this loss pattern and expected dilution as reasons to question how much downside protection exists if growth falls short of forecasts. 🐻 MediWound Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for MediWound on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With such a mixed picture of risks and rewards, it makes sense to look past the headlines, move quickly, and test the numbers for yourself. Then weigh up the company's potential by checking the 2 key rewards and 2 important warning signs

See What Else Is Out There

MediWound's persistent losses, premium 12.7x P/S multiple, and lack of near term profitability expectations leave investors carrying a lot of execution risk.

If you want ideas where pricing looks more grounded in current fundamentals, use the 64 resilient stocks with low risk scores to quickly spot stocks that aim for resilience over uncertainty.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.